The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic and predictive significance of pre- and post-operative plasma tumor markers in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery: Insights from a single-center study.
 
Abdelrahman M.G. Yousef
No Relationships to Disclose
 
Mahmoud M.G. Yousef
No Relationships to Disclose
 
Mohammad A. A. Zeineddine
No Relationships to Disclose
 
Ichiaki Ito
No Relationships to Disclose
 
Saikat Chowdhury
Patents, Royalties, Other Intellectual Property - Sarkar, R.R., Chowdhury, S. (2021) Method to predict pathological grade and to identify drug targets against glioma tumor. US17/154,379 filed on July 29, 2021. Patent Pending; Sarkar, R.R., Ganguli, P., Chowdhury, S. (2020) Identification of minimal combinations of molecules that act as probable immunostimulators against Leishmaniasis. US15/776,008 filed on January 16, 2020. Patent Pending
 
Yue Gu
Employment - MD Anderson Cancer Center
Research Funding - MD Anderson Cancer Center
 
Mark Knafl
No Relationships to Disclose
 
Jeff Jin
No Relationships to Disclose
 
Paul Edelkamp
No Relationships to Disclose
 
Abhineet Uppal
No Relationships to Disclose
 
Neal Bhutiani
No Relationships to Disclose
 
Kristin Alfaro-Munoz
Consulting or Advisory Role - Abbvie; SDP Oncology
 
Neus Neus Bota-Rabassedas
No Relationships to Disclose
 
Beth A Helmink
No Relationships to Disclose
 
Michael White
No Relationships to Disclose
 
Melissa Taggart
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Keith F. Fournier
No Relationships to Disclose
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics